



SPECIAL APPLICATION FORM 2

Application form for subscription of shares in Oasmia Pharmaceutical AB (publ) without pre-emptive right

Subscription period:	June 21 – July 5, 2017
Subscription price:	3,25 SEK
Allotment of shares:	Notification of allotment is made through distribution of contract note
Payment day:	Two business days after issuance of the contract note

N.B. This application form shall not be used if you intend to only subscribe for shares by exercise of your subscription rights.

Details and conditions in full are set out in the prospectus published issued in June 2017 by the Board of Directors of Oasmia Pharmaceutical AB (publ). In an assessment of the company's future development, it is also important to consider the relevant risks. Each investor must make its own assessment of the impact of these risks by taking part of all information available. The prospectus is available for downloading at www.aktieinvest.se and www.oasmia.com.

A. The undersigned hereby applies for subscription without pre-emptive right as follows:

number of shares in Oasmia Pharmaceutical AB (publ) at the above stated subscription price.

Number of shares subscribed for with pre-emptive right:

B. Delivery of shares is to be made to the following:

VP-account: | | | | | | | | | |

Note! Shareholders whose shares are nominee-registered subscribes through their broker.

C. Personal Details:

First Name and Surname/ Company Name:		Social Security Number/ Registration Number:	
Postal Address:		E-mail Address:	
Postal Code:	City/ Town:	Country:	
Place and Date:		Telephone:	
Signed by the owner (or when applicable, company signatory or guardian)			

Note! If the subscription comprises more than 43 000 shares, a copy of a valid ID documentation must be enclosed to the application form for it to be valid. For a legal entity a copy of the registration certificate, showing the company signatory, as well as a copy of the signatory's ID documentation must be enclosed.

The undersigned acknowledge and agrees that:

- This application is binding, however an incomplete or incorrectly completed application may be disregarded.
- Aktieinvest FK AB is hereby authorized to execute the subscription of shares according to the terms and conditions set forth in the prospectus issued in June 2017 by the Board of Directors of Oasmia Pharmaceutical AB (publ).
- In the event of over subscription, allotment may comprise a lower number of shares or not be made at all.
- Personal data given in connection with this application or otherwise recorded in connection therewith is treated by Aktieinvest FK AB for preparation and administration within the assignment. Other companies that Aktieinvest FK AB cooperates with within this assignment may also access this personal data.

D. Send your application

by post to:

Aktieinvest FK AB

Emittentservice

SE-113 89 Stockholm

or scanned by e-mail to:

emittentservice@aktieinvest.se